{"mainPropery":{"diseaseId":10324,"diseaseName":"Mild phenylketonuria","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10324/mild-phenylketonuria","synonyms":["Mild PKU","mPKU","Variant phenylketonuria","Variant PKU"],"synonyms-with-source":[{"name":"Mild PKU","source":"OrphaData.Org"},{"name":"mPKU","source":"OrphaData.Org"},{"name":"Variant phenylketonuria","source":"Orphanet"},{"name":"Variant PKU","source":"Orphanet"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"79253"},{"identifierType":"UMLS","identifierId":"C0543528"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"},{"diseaseTypeId":37,"diseaseTypeName":"Newborn Screening"}],"organizations":[],"resource descriptions":[{"id":350,"resourceId":1167,"resourceName":"Baby's First Test","descriptionText":"<a href='https://www.babysfirsttest.org/newborn-screening/conditions/benign-hyperphenylalaninemia' target='_blank'>Baby's First Test</a> is the nation's newborn screening education center for families and providers. This site provides information and resources about screening at the local, state, and national levels and serves as the Clearinghouse for newborn screening information.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":824,"resourceId":1547,"resourceName":"Benign hyperphenylalaninemia","descriptionText":"The <a href='http://newbornscreeningcodes.nlm.nih.gov/nb/sc/condition/H-PHE ' target='_blank'>Newborn Screening Coding and Terminology Guide</a> has information on the standard codes used for  newborn screening tests. Using these standards helps compare data across different laboratories. This resource was created by the National Library of Medicine.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1321,"resourceId":1982,"resourceName":"National Newborn Screening and Global Resource Center","descriptionText":"<a href='https://www.newbornscreening.info/iva-isovaleric-acidemia/' target='_blank'>National Newborn Screening and Global Resource Center</a> (NNSGRC) provides information and resources in the area of newborn screening and genetics to benefit health professionals, the public health community, consumers and government officials.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=79253' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1535,"resourceId":2166,"resourceName":"ACTion (ACT) sheet","descriptionText":"An  <a href='https://www.acmg.net/PDFLibrary/Phenylalanine.pdf' target='_blank'>ACTion (ACT) sheet </a> is available for this condition that describes the short-term actions a health professional should follow when an infant has a positive newborn screening result. ACT sheets were developed by experts in collaboration with the American College of Medical Genetics.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=pku' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1546,"resourceId":2174,"resourceName":"Algorithm","descriptionText":"An <a href='https://www.acmg.net/PDFLibrary/Phenylalanine-Algorithm.pdf' target='_blank'>Algorithm</a> flowchart is available for this condition for determining the final diagnosis in an infant with a positive newborn screening result. Algorithms are developed by experts in collaboration with the American College of Medical Genetics.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/Orphanet:79253' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2303,"resourceId":3537,"resourceName":"NCATS Rare Disease Patient Video Series","descriptionText":"In this <a target=\"_blank\" href=\"https://www.youtube.com/watch?v=btSQQYcxnjk\">NCATS Video Profile</a>, <strong><span style=\"font-weight: normal;\">Jennifer Payne discusses living with phenylketonuria (PKU). Left untreated, PKU results in psychological disorders, neurological deterioration, mental illness and brain damage. <strong><span style=\"font-weight: normal;\">Dietary management and</span></strong> access to medical foods are a critical part of PKU care.</span></strong>","resourceClassificationName":"Living With","resourceClassificationSectionName":"Parent and Caregiver Resources"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Mild phenylketonuria. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Mild phenylketonuria:<br />\r\n<a href='https://nbs.patientcrossroads.org' target='_blank'>NBS Connect</a><br /><a href='https://pku.iamrare.org/' target='_blank'>PKU Patient Registry</a><br /><a href='https://pku.iamrare.org/' target='_blank'>The PKU Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":9886,"questionText":"What is mild phenylketonuria?","answerText":"<strong>Mild phenylketonuria </strong>is a rare form of <a href=\"https://rarediseases.info.nih.gov/gard/7383/phenylketonuria/resources/1\" target=\"_blank\">phenylketouria</a> (PKU variant), an <a href=\"http://www.wadsworth.org/newborn-screening/inborn-errors-of-2\" target=\"_blank\">inborn error of amino acid metabolism</a>, characterized by symptoms of PKU of mild to moderate severity. Patients with blood phenylalanine concentrations of 600-1,200 micromol/L are considered to have mild PKU. Clinical signs include reduced cognitive function and behavioral and developmental disorders. It is caused by certain <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\" tabindex=\"-1\">mutations</a>  in the <a href=\"http://ghr.nlm.nih.gov/gene/PAH\" target=\"_blank\" tabindex=\"-1\"><em>PAH</em> gene</a> which result in slightly higher activity of the phenylalanine hydroxylase compared with the classic phenylketonuria where there is a complete or near-complete deficiency of phenylalanine hydroxylase activity. Inheritance is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\" tabindex=\"-1\">autosomal recessive</a>. Treatment is with a diet low in phenylalanine (patients can have up to 400-600 mg/day of phenylalanine).[10294][10296]","dateModified":"2015-12-28T23:08:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":70,"genericName":"Sapropterin","tradeName":"Kuvan","tradeLink":"http://www.kuvan.com/","manufacturer":"","sponsor":"Biomarin Pharmaceutical Inc.","indication":"December 2014 approved to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU).  Kuvan is to be used in conjunction with a Phe-restricted diet.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/kuvan","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a608020.html"},{"productId":721,"genericName":"Pegvaliase","tradeName":"Palynziq","tradeLink":"http://www.palynziq.com/","manufacturer":"","sponsor":"BioMarin Pharmaceutical","indication":"May 2018 approved to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.","drugInformationLink":"","medlinePlusLink":""}],"EncodedName":"Mild_phenylketonuria"}